Literature DB >> 6259979

Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside.

R B Pollard, P R Egbert, J G Gallagher, T C Merigan.   

Abstract

Cytomegalovirus (CMV) retinitis presents with typical ophthalmologic appearance in patients with underlying immunosuppressive conditions. Fourteen patients with this disorder were diagnosed by culture of cytomegalovirus from urine or throat specimens, elevated complement fixation titers to cytomegalovirus, and characteristic funduscopic appearance. Ten of 11 had decreased CMV-specific cell-mediated immune responses. Three of seven who received no specific therapy improved after decreasing dosages of immunosuppressive drugs. Seven patients with progressive disease despite minimal immunosuppressive therapy were treated with adenine arabinoside at doses from 1 to 20 mg/kg of body weight per day. Daily dosages of 20 mg/kg . d in five patients were associated with decreased inflammatory activity and improvement of retinal lesions and quantitative decreases in urinary virus excretion. Adenine arabinoside administration was associated with significant gastrointestinal, hematologic, and neurologic side effects. Adenine arabinoside may have some beneficial effect on selected patients with progressive CMV retinitis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6259979     DOI: 10.7326/0003-4819-93-5-655

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Treatment of cytomegalovirus retinitis: A growing number of options.

Authors:  S D Shafran; J M Conly
Journal:  Can J Infect Dis       Date:  1996-11

2.  Analysis of the relationship between postoperative ophthalmic complications and dialysis time of pre-kidney transplantation.

Authors:  Yao-Lei Wang; Fan Qi; Jin-Liang Xie; Lin Qi; Cheng Zhou; Xiang-Rong Zhu; Xiang Ding; Bo Yang; Peng Jin
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

3.  Treatment of immune recovery vitritis with local steroids.

Authors:  H W Henderson; S M Mitchell
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

4.  Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U).

Authors:  J Orellana; S A Teich; J S Winterkorn; U Mathur-Wagh; S Handwerger; H Schlamm; S C Malamud; S R Yancovitz; D M Cederberg; D S Mildvan
Journal:  Br J Ophthalmol       Date:  1988-07       Impact factor: 4.638

5.  Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression.

Authors:  G L Daikos; J Pulido; S B Kathpalia; G G Jackson
Journal:  Br J Ophthalmol       Date:  1988-07       Impact factor: 4.638

6.  Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.

Authors:  P S Ganly; C Arthur; J M Goldman; W E Schulenburg
Journal:  Postgrad Med J       Date:  1988-05       Impact factor: 2.401

7.  Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients.

Authors:  M L Jordan; R L Hrebinko; J S Dummer; D P Hickey; R Shapiro; C A Vivas; R L Simmons; T E Starzl; T R Hakala
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

8.  High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients.

Authors:  R L Saltzman; M R Quirk; M C Jordan
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

9.  Activity of trifluorothymidine against cytomegalovirus.

Authors:  J R Wingard; R K Stuart; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

10.  Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS).

Authors:  A H Friedman; J Orellana; W R Freeman; M H Luntz; M B Starr; M L Tapper; I Spigland; H Roterdam; R Mesa Tejada; S Braunhut; D Mildvan; U Mathur
Journal:  Br J Ophthalmol       Date:  1983-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.